Biomarker of dermatomyositis with rapidly progressive interstitial lung disease Clinically amyopathic dermatomyositis (CADM), dermatomyositis without muscle weakness, is associated with elevated rates of rapidly progressive interstitial lung disease (RP-ILD), which is extremely resistant to treatment. The prognosis is poor after
MESACUP™ anti-MDA5 TEST
